Effective Start Date,Effective End Date,DIN,Trade name,Strength,Dosage form,DBP (raw),Ex Factory Wholesale Price,Ex Factory Wholesale Unit,Local Pack Description,PK keyword present,Public With VAT Price,RI Price,Reimbursable Status,Reimbursable Price,Reimbursable Rate,Reimbursable Notes,Copayment Value
2025-10-20,,02541769,Evkeeza,150mg/mL,Inj Sol,$29.4600/mg,29.46,mg,150mg/mL Inj Sol,No,31.8168,31.8168,FULLY REIMBURSABLE,31.8168,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-10-20,,02543931,Uplizna,10mg/mL,Inj Sol,"$2,562.3000/mL",2562.3,mL,10mg/mL Inj Sol,No,2767.284,2767.284,FULLY REIMBURSABLE,2767.284,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-10-20,,02544903,Velsipity,2mg,Tab,$43.1000,43.1,,2mg Tab,No,46.548,46.548,FULLY REIMBURSABLE,46.548,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-10-10,,02537745,Imcivree,10mg/mL,Inj Sol-Vial Pk,$4022.9046/Vial Pk,4022.9046,Vial Pk,10mg/mL Inj Sol-Vial Pk,Yes,4344.736968,4344.736968,FULLY REIMBURSABLE,4344.736968,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-09-29,,02495058,Xospata,40mg,Tab,$276.6847,276.6847,,40mg Tab,No,298.819476,298.819476,FULLY REIMBURSABLE,298.819476,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-09-16,,02543079,Epidiolex,100mg/mL,Oral Sol-100mL Pk,$1424.5400/Pk,1424.54,Pk,100mg/mL Oral Sol-100mL Pk,Yes,1538.5032,1538.5032,FULLY REIMBURSABLE,1538.5032,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-09-10,,02554267,Brukinsa,160mg,Tab,$135.9666,135.9666,,160mg Tab,No,146.843928,146.843928,FULLY REIMBURSABLE,146.843928,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-08-29,,02549980,Tibsovo,250mg,Tab,$332.6000,332.6,,250mg Tab,No,359.208,359.208,FULLY REIMBURSABLE,359.208,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-07-07,,02548909,Wainua,45mg/0.8mL,Inj Sol-0.8mL Pref Autoinj (Preservative-Free),$1059.5629/mg,1059.5629,mg,45mg/0.8mL Inj Sol-0.8mL Pref Autoinj (Preservative-Free),No,1144.327932,1144.327932,FULLY REIMBURSABLE,1144.327932,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-06-24,,02544733,Truqap,160mg,Tab,$147.6000,147.6,,160mg Tab,No,159.408,159.408,FULLY REIMBURSABLE,159.408,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-06-24,,02544741,Truqap,200mg,Tab,$147.6000,147.6,,200mg Tab,No,159.408,159.408,FULLY REIMBURSABLE,159.408,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-06-12,,09858357,Besremi,500mcg/mL,Inj Sol-Pref Syr,$4495.0000,4495.0,,500mcg/mL Inj Sol-Pref Syr,No,4854.6,4854.6,FULLY REIMBURSABLE,4854.6,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-05-07,,02524627,Sohonos,1 mg,Cap,$324.2200,324.22,,1 mg Cap,No,350.1576,350.1576,FULLY REIMBURSABLE,350.1576,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-05-07,,02524635,Sohonos,1.5 mg,Cap,$486.3300,486.33,,1.5 mg Cap,No,525.2364,525.2364,FULLY REIMBURSABLE,525.2364,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-05-07,,02524643,Sohonos,2.5 mg,Cap,$810.5500,810.55,,2.5 mg Cap,No,875.394,875.394,FULLY REIMBURSABLE,875.394,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-05-07,,02524651,Sohonos,5 mg,Cap,$1621.1000,1621.1,,5 mg Cap,No,1750.788,1750.788,FULLY REIMBURSABLE,1750.788,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-05-07,,02524678,Sohonos,10 mg,Cap,$3242.2000,3242.2,,10 mg Cap,No,3501.576,3501.576,FULLY REIMBURSABLE,3501.576,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02511355,Kesimpta,20 mg /0.4 mL,Inj Sol-0.4 mL Pref SensoReady Pen Pk,$2318.7400,2318.74,,20 mg /0.4 mL Inj Sol-0.4 mL Pref SensoReady Pen Pk,Yes,2504.2392,2504.2392,FULLY REIMBURSABLE,2504.2392,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02409623,Mekinist,0.5mg,Tab,$88.2200,88.22,,0.5mg Tab,No,95.2776,95.2776,FULLY REIMBURSABLE,95.2776,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02409607,Tafinlar,50mg,Cap,$51.3300,51.33,,50mg Cap,No,55.4364,55.4364,FULLY REIMBURSABLE,55.4364,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02409615,Tafinlar,75mg,Cap,$76.8500,76.85,,75mg Cap,No,82.998,82.998,FULLY REIMBURSABLE,82.998,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02369613,Banzel,100mg,Tab,$0.9524,0.9524,,100mg Tab,No,1.028592,1.028592,FULLY REIMBURSABLE,1.028592,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02029448,Elmiron,100mg,Cap,$4.6212,4.6212,,100mg Cap,No,4.990896,4.990896,FULLY REIMBURSABLE,4.990896,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02491087,Emgality,120mg/mL,Inj Sol-1mL Pref Pen (Preservative-Free),$600.3300,600.33,,120mg/mL Inj Sol-1mL Pref Pen (Preservative-Free),No,648.3564,648.3564,FULLY REIMBURSABLE,648.3564,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02491060,Emgality,120mg/mL,Inj Sol-1mL Pref Syr (Preservative-Free),$600.3300,600.33,,120mg/mL Inj Sol-1mL Pref Syr (Preservative-Free),No,648.3564,648.3564,FULLY REIMBURSABLE,648.3564,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02230845,Flolan,0.5mg,Inj-Vial Pk,$25.2900,25.29,,0.5mg Inj-Vial Pk,Yes,27.3132,27.3132,FULLY REIMBURSABLE,27.3132,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02230848,Flolan,1.5mg/Vial,Inj-5mL Vial Pk,$50.5700,50.57,,1.5mg/Vial Inj-5mL Vial Pk,Yes,54.6156,54.6156,FULLY REIMBURSABLE,54.6156,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02470152,Humalog,100U/mL,Inj Sol-Pref Pen 5x3mL Pk (Junior KwikPen),$76.5000,76.5,,100U/mL Inj Sol-Pref Pen 5x3mL Pk (Junior KwikPen),Yes,82.62,82.62,FULLY REIMBURSABLE,82.62,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02403412,Humalog Kwikpen,100U/mL,Inj Sol-5x3mL Pk,$71.8500,71.85,,100U/mL Inj Sol-5x3mL Pk,Yes,77.598,77.598,FULLY REIMBURSABLE,77.598,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02243077,Humatrope,6mg/Cart,Inj Pd-6mg Cart Pk with Diluent,$364.6800,364.68,,6mg/Cart Inj Pd-6mg Cart Pk with Diluent,Yes,393.8544,393.8544,FULLY REIMBURSABLE,393.8544,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02243078,Humatrope,12mg/Cart,Inj Pd-12mg Cart Pk with Diluent,$729.3500,729.35,,12mg/Cart Inj Pd-12mg Cart Pk with Diluent,Yes,787.698,787.698,FULLY REIMBURSABLE,787.698,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02243079,Humatrope,24mg/Cart,Inj Pd-24mg Cart Pk with Diluent,$1458.7100,1458.71,,24mg/Cart Inj Pd-24mg Cart Pk with Diluent,Yes,1575.4068,1575.4068,FULLY REIMBURSABLE,1575.4068,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02230418,Imitrex,5mg/Dose,Nas Sp-2 Dose Pk,$38.8800,38.88,,5mg/Dose Nas Sp-2 Dose Pk,Yes,41.9904,41.9904,FULLY REIMBURSABLE,41.9904,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02230420,Imitrex,20mg/Dose,Nas Sp,$19.9950,19.995,,20mg/Dose Nas Sp,No,21.5946,21.5946,FULLY REIMBURSABLE,21.5946,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02240115,Lamictal,5mg,Chew Tab,$0.2300,0.23,,5mg Chew Tab,No,0.2484,0.2484,FULLY REIMBURSABLE,0.2484,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02484056,Lenvima,4mg/Dose,Cap,$39.2506,39.2506,,4mg/Dose Cap,No,42.390648,42.390648,FULLY REIMBURSABLE,42.390648,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02468220,Lenvima,8mg/Dose,Cap,$79.3079,79.3079,,8mg/Dose Cap,No,85.652532,85.652532,FULLY REIMBURSABLE,85.652532,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02484129,Lenvima,12mg/Dose,Cap,$117.7519,117.7519,,12mg/Dose Cap,No,127.172052,127.172052,FULLY REIMBURSABLE,127.172052,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02450321,Lenvima,10mg per dose,Daily Dose Pk,$86.9775,86.9775,,10mg per dose Daily Dose Pk,Yes,93.9357,93.9357,FULLY REIMBURSABLE,93.9357,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02450313,Lenvima,14mg per dose,Daily Dose Pk,$135.1036,135.1036,,14mg per dose Daily Dose Pk,Yes,145.911888,145.911888,FULLY REIMBURSABLE,145.911888,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02450305,Lenvima,20mg per dose,Daily Dose Pk,$202.6673,202.6673,,20mg per dose Daily Dose Pk,Yes,218.880684,218.880684,FULLY REIMBURSABLE,218.880684,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02450291,Lenvima,24mg per dose,Daily Dose Pk,$270.2068,270.2068,,24mg per dose Daily Dose Pk,Yes,291.823344,291.823344,FULLY REIMBURSABLE,291.823344,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02425629,Lucentis,10mg/mL,Inj Sol-Pref Syr 0.165mL Pk,$1744.5000,1744.5,,10mg/mL Inj Sol-Pref Syr 0.165mL Pk,Yes,1884.06,1884.06,FULLY REIMBURSABLE,1884.06,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02296810,Lucentis,10mg/mL,Inj Sol-0.23mL Vial Pk,$1744.5000,1744.5,,10mg/mL Inj Sol-0.23mL Vial Pk,Yes,1884.06,1884.06,FULLY REIMBURSABLE,1884.06,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02244353,NovoRapid Penfill,100U/mL,Inj Sol-5x3mL Pk,$64.8200,64.82,,100U/mL Inj Sol-5x3mL Pk,Yes,70.0056,70.0056,FULLY REIMBURSABLE,70.0056,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02492989,Nucala,100mg/mL,Inj Sol-Pref Auto Inj,$2452.5800,2452.58,,100mg/mL Inj Sol-Pref Auto Inj,No,2648.7864,2648.7864,FULLY REIMBURSABLE,2648.7864,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02492997,Nucala,100mg/mL,Inj Sol-Pref Syr,$2452.5800,2452.58,,100mg/mL Inj Sol-Pref Syr,No,2648.7864,2648.7864,FULLY REIMBURSABLE,2648.7864,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02248077,Pegasys,180mcg/0.5mL,Inj Sol-Pref Syr-0.5mL Pk,$436.0800,436.08,,180mcg/0.5mL Inj Sol-Pref Syr-0.5mL Pk,Yes,470.9664,470.9664,FULLY REIMBURSABLE,470.9664,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02443651,pH 12 Sterile Diluent for Flolan,94mg/73.3mg/50mL Vial,Inj Sol-50mL Vial Pk,$13.2350,13.235,,94mg/73.3mg/50mL Vial Inj Sol-50mL Vial Pk,Yes,14.2938,14.2938,FULLY REIMBURSABLE,14.2938,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02244310,Renagel,800mg,Tab,$1.8250,1.825,,800mg Tab,No,1.971,1.971,FULLY REIMBURSABLE,1.971,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02516918,Retevmo,40mg,Cap,$76.1198,76.1198,,40mg Cap,No,82.209384,82.209384,FULLY REIMBURSABLE,82.209384,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02516926,Retevmo,80mg,Cap,$152.2400,152.24,,80mg Cap,No,164.4192,164.4192,FULLY REIMBURSABLE,164.4192,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02237971,Saizen,5mg,Inj Pd-5mg vial Pk,$235.2500,235.25,,5mg Inj Pd-5mg vial Pk,Yes,254.07,254.07,FULLY REIMBURSABLE,254.07,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02350122,Saizen,6mg/Cart (5.83mg/mL),Inj Cart,$296.3800,296.38,,6mg/Cart (5.83mg/mL) Inj Cart,No,320.0904,320.0904,FULLY REIMBURSABLE,320.0904,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02350130,Saizen,12mg/Cart (8mg/mL),Inj Cart,$592.7600,592.76,,12mg/Cart (8mg/mL) Inj Cart,No,640.1808,640.1808,FULLY REIMBURSABLE,640.1808,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02350149,Saizen,20mg/Cart (8mg/mL),Inj Cart,$987.9500,987.95,,20mg/Cart (8mg/mL) Inj Cart,No,1066.986,1066.986,FULLY REIMBURSABLE,1066.986,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02272199,Somavert,10mg,Pd for Inj-Vial Pk,$139.0400,139.04,,10mg Pd for Inj-Vial Pk,Yes,150.1632,150.1632,FULLY REIMBURSABLE,150.1632,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02272202,Somavert,15mg,Pd for Inj-Vial Pk,$208.5600,208.56,,15mg Pd for Inj-Vial Pk,Yes,225.2448,225.2448,FULLY REIMBURSABLE,225.2448,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02272210,Somavert,20mg,Pd for Inj-Vial Pk,$278.0800,278.08,,20mg Pd for Inj-Vial Pk,Yes,300.3264,300.3264,FULLY REIMBURSABLE,300.3264,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02448831,Somavert,25mg,Pd for Inj-Vial Pk,$347.6000,347.6,,25mg Pd for Inj-Vial Pk,Yes,375.408,375.408,FULLY REIMBURSABLE,375.408,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02448858,Somavert,30mg,Pd for Inj-Vial Pk,$417.1200,417.12,,30mg Pd for Inj-Vial Pk,Yes,450.4896,450.4896,FULLY REIMBURSABLE,450.4896,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02529548,Tezspire,110mg/mL,Inj Sol-1.91mL Pref Syr (Preservative-Free),$2027.6300,2027.63,,110mg/mL Inj Sol-1.91mL Pref Syr (Preservative-Free),No,2189.8404,2189.8404,FULLY REIMBURSABLE,2189.8404,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02529556,Tezspire,110mg/mL,Inj Sol-1.91mL Pref Pen (Preservative-Free),$2027.6300,2027.63,,110mg/mL Inj Sol-1.91mL Pref Pen (Preservative-Free),No,2189.8404,2189.8404,FULLY REIMBURSABLE,2189.8404,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02487098,Verzenio,50mg,Tab,$116.9725,116.9725,,50mg Tab,No,126.3303,126.3303,FULLY REIMBURSABLE,126.3303,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02487101,Verzenio,100mg,Tab,$115.8889,115.8889,,100mg Tab,No,125.160012,125.160012,FULLY REIMBURSABLE,125.160012,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-30,,02487128,Verzenio,150mg,Tab,$116.2175,116.2175,,150mg Tab,No,125.5149,125.5149,FULLY REIMBURSABLE,125.5149,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-22,,02541599,Vyvgart,400 mg /20 mL,Inj Sol-Vial Pk,$7900.0000/Vial,7900.0,Vial,400 mg /20 mL Inj Sol-Vial Pk,Yes,8532.0,8532.0,FULLY REIMBURSABLE,8532.0,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-14,,02530139,Koselugo,10 mg,Cap,$122.6000,122.6,,10 mg Cap,No,132.408,132.408,FULLY REIMBURSABLE,132.408,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-04-14,,02530147,Koselugo,25 mg,Cap,$306.5000,306.5,,25 mg Cap,No,331.02,331.02,FULLY REIMBURSABLE,331.02,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02458136,Alecensaro,150 mg,Cap,$45.3375,45.3375,,150 mg Cap,No,48.9645,48.9645,FULLY REIMBURSABLE,48.9645,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,00728276,Burinex,5 mg,Tab,$3.1690,3.169,,5 mg Tab,No,3.42252,3.42252,FULLY REIMBURSABLE,3.42252,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,00728284,Burinex,1 mg,Tab,$0.8300,0.83,,1 mg Tab,No,0.8964,0.8964,FULLY REIMBURSABLE,0.8964,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02144328,Carnitor,330 mg,Tab,$3.7857,3.7857,,330 mg Tab,No,4.088556,4.088556,FULLY REIMBURSABLE,4.088556,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02144344,Carnitor,200 mg / mL,Inj,$87.9400,87.94,,200 mg / mL Inj,No,94.9752,94.9752,FULLY REIMBURSABLE,94.9752,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02331675,Cimzia,200 mg / mL,Pre-Filled Syringe,$715.2400,715.24,,200 mg / mL Pre-Filled Syringe,No,772.4592,772.4592,FULLY REIMBURSABLE,772.4592,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02465574,Cimzia,200 mg / mL,Inj Sol-Pref Pen,$715.2400,715.24,,200 mg / mL Inj Sol-Pref Pen,No,772.4592,772.4592,FULLY REIMBURSABLE,772.4592,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02512556,Dojolvi,100% w/w,O/L-500 mL Pk,$6683.2500/Pk,6683.25,Pk,100% w/w O/L-500 mL Pk,Yes,7217.91,7217.91,FULLY REIMBURSABLE,7217.91,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02436841,Entyvio,300 mg,Inj Sol-Vial,$3711.2500,3711.25,,300 mg Inj Sol-Vial,No,4008.15,4008.15,FULLY REIMBURSABLE,4008.15,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02497867,Entyvio,108 mg /0.68 mL,Inj Sol-0.68 mL Pref Pen (Preservative-Free),$927.8050,927.805,,108 mg /0.68 mL Inj Sol-0.68 mL Pref Pen (Preservative-Free),No,1002.0294,1002.0294,FULLY REIMBURSABLE,1002.0294,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02497875,Entyvio,108 mg /0.68 mL,Inj Sol-0.68 mL Pref Pen (Preservative-Free),$927.8050,927.805,,108 mg /0.68 mL Inj Sol-0.68 mL Pref Pen (Preservative-Free),No,1002.0294,1002.0294,FULLY REIMBURSABLE,1002.0294,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02409267,Erivedge,150 mg,Cap,$336.7421,336.7421,,150 mg Cap,No,363.681468,363.681468,FULLY REIMBURSABLE,363.681468,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02241377,Metadol,10 mg / mL,O/L,$0.5398/ mL,0.5398,mL,10 mg / mL O/L,No,0.582984,0.582984,FULLY REIMBURSABLE,0.582984,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02247694,Metadol,1 mg / mL,O/L,$0.1493/ mL,0.1493,mL,1 mg / mL O/L,No,0.161244,0.161244,FULLY REIMBURSABLE,0.161244,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02129043,Orgaran,750U/Vial,Inj-Vial Pk,$33.0495,33.0495,,750U/Vial Inj-Vial Pk,Yes,35.69346,35.69346,FULLY REIMBURSABLE,35.69346,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02046733,Pulmozyme,1 mg / mL,Inj-2.5 mL Pk,$43.8030,43.803,,1 mg / mL Inj-2.5 mL Pk,Yes,47.30724,47.30724,FULLY REIMBURSABLE,47.30724,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02500833,Qinlock,50 mg,Tab,$226.0538,226.0538,,50 mg Tab,No,244.138104,244.138104,FULLY REIMBURSABLE,244.138104,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02237319,Rebif,22mcg,Inj-Syr Pk,$179.1367,179.1367,,22mcg Inj-Syr Pk,Yes,193.467636,193.467636,FULLY REIMBURSABLE,193.467636,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02237320,Rebif,44mcg,Inj-Syr Pk,$218.0833,218.0833,,44mcg Inj-Syr Pk,Yes,235.529964,235.529964,FULLY REIMBURSABLE,235.529964,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02318253,Rebif,66mcg,Inj-Cart Pk,$537.4100,537.41,,66mcg Inj-Cart Pk,Yes,580.4028,580.4028,FULLY REIMBURSABLE,580.4028,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02318261,Rebif,132mcg,Inj-Cart Pk,$654.2375,654.2375,,132mcg Inj-Cart Pk,Yes,706.5765,706.5765,FULLY REIMBURSABLE,706.5765,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02495007,Rozlytrek,100 mg,Cap,$51.2510,51.251,,100 mg Cap,No,55.35108,55.35108,FULLY REIMBURSABLE,55.35108,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02495015,Rozlytrek,200 mg,Cap,$102.5023,102.5023,,200 mg Cap,No,110.702484,110.702484,FULLY REIMBURSABLE,110.702484,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02510839,Vyepti,100 mg / mL,Inj Sol-1 mL Vial (Preservative-Free),$1847.5706,1847.5706,,100 mg / mL Inj Sol-1 mL Vial (Preservative-Free),No,1995.376248,1995.376248,FULLY REIMBURSABLE,1995.376248,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02542269,Vyepti,300 mg /3 mL,Inj Sol-3 mL Vial (Preservative-Free),$1847.5706,1847.5706,,300 mg /3 mL Inj Sol-3 mL Vial (Preservative-Free),No,1995.376248,1995.376248,FULLY REIMBURSABLE,1995.376248,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02240325,Xenical,120 mg,Cap,$1.9222,1.9222,,120 mg Cap,No,2.075976,2.075976,FULLY REIMBURSABLE,2.075976,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-03-31,,02380242,Zelboraf,240 mg,Tab,$38.2275,38.2275,,240 mg Tab,No,41.2857,41.2857,FULLY REIMBURSABLE,41.2857,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-02-28,,02470489,Benlysta SC,200 mg /ml,Inj Sol-Autoinj Pref Syr (Preservative-Free),395.3975/Pref Syr,395.3975,Pref Syr,200 mg /ml Inj Sol-Autoinj Pref Syr (Preservative-Free),No,427.0293,427.0293,FULLY REIMBURSABLE,427.0293,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-02-27,,02538555,Akeega,50 mg /500 mg,Tab,$147.1000,147.1,,50 mg /500 mg Tab,No,158.868,158.868,FULLY REIMBURSABLE,158.868,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-02-27,,02538563,Akeega,100 mg /500 mg,Tab,$147.1000,147.1,,100 mg /500 mg Tab,No,158.868,158.868,FULLY REIMBURSABLE,158.868,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-02-13,,02527693,Orladeyo,150 mg,Cap,$850.000,850.0,,150 mg Cap,No,918.0,918.0,FULLY REIMBURSABLE,918.0,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-01-31,,02397447,Caripul,0.5mg,Inj-10mL Vial Pk,$20.7800,20.78,,0.5mg Inj-10mL Vial Pk,Yes,22.4424,22.4424,FULLY REIMBURSABLE,22.4424,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-01-31,,02397455,Caripul,1.5mg,Inj-10mL Vial Pk,$41.6800,41.68,,1.5mg Inj-10mL Vial Pk,Yes,45.0144,45.0144,FULLY REIMBURSABLE,45.0144,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-01-31,,02489597,Evenity,105mg/1.17mL,Inj Sol-1.17mL Pref Syr (Preservative-Free),$353.0800,353.08,,105mg/1.17mL Inj Sol-1.17mL Pref Syr (Preservative-Free),No,381.3264,381.3264,FULLY REIMBURSABLE,381.3264,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2025-01-31,,00725765,Meperidine Hydrochloride Injection USP,50mg/mL,Inj Sol-1mL Pk,$3.8110,3.811,,50mg/mL Inj Sol-1mL Pk,Yes,4.11588,4.11588,FULLY REIMBURSABLE,4.11588,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-12-13,,02542420,Amvuttra,25mg/0.5mL,Inj Sol-0.5mL Pref Syr Pk,$5721.6400/mg,5721.64,mg,25mg/0.5mL Inj Sol-0.5mL Pref Syr Pk,Yes,6179.3712,6179.3712,FULLY REIMBURSABLE,6179.3712,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-11-25,,02528908,Welireg,40mg,Tab,$213.3300,213.33,,40mg Tab,No,230.3964,230.3964,FULLY REIMBURSABLE,230.3964,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-11-04,,02539845,Omvoh,100 mg / mL,Inj Sol-1 mL Prefilled Pen (Preservative-Free),$1268.0700,1268.07,,100 mg / mL Inj Sol-1 mL Prefilled Pen (Preservative-Free),No,1369.5156,1369.5156,FULLY REIMBURSABLE,1369.5156,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-11-04,,02539853,Omvoh,100 mg / mL,Inj Sol-1 mL Prefilled Syr (Preservative-Free),$1268.0700,1268.07,,100 mg / mL Inj Sol-1 mL Prefilled Syr (Preservative-Free),No,1369.5156,1369.5156,FULLY REIMBURSABLE,1369.5156,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-11-04,,02539861,Omvoh,20 mg / mL,Inj Sol-15 mL Vial Pk (Preservative Free),$2536.1400,2536.14,,20 mg / mL Inj Sol-15 mL Vial Pk (Preservative Free),Yes,2739.0312,2739.0312,FULLY REIMBURSABLE,2739.0312,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-09-05,,02537702,Vyalev,240 mg / mL & 12 mg / mL,Inj Sol-10 mL Vial Pk,169.8100/Vial,169.81,Vial,240 mg / mL & 12 mg / mL Inj Sol-10 mL Vial Pk,Yes,183.3948,183.3948,FULLY REIMBURSABLE,183.3948,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-08-26,,02532549,Camzyos,2.5 mg,Cap,61.6000,61.6,,2.5 mg Cap,No,66.528,66.528,FULLY REIMBURSABLE,66.528,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-08-26,,02532557,Camzyos,5 mg,Cap,61.6000,61.6,,5 mg Cap,No,66.528,66.528,FULLY REIMBURSABLE,66.528,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-08-26,,02532565,Camzyos,10 mg,Cap,61.6000,61.6,,10 mg Cap,No,66.528,66.528,FULLY REIMBURSABLE,66.528,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-08-26,,02532573,Camzyos,15 mg,Cap,61.6000,61.6,,15 mg Cap,No,66.528,66.528,FULLY REIMBURSABLE,66.528,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-07-29,,02525755,Oxlumo,94.5 mg /0.5 mL,Inj Sol-0.5 mL Vial Pk,$1024.9241/ mg,1024.9241,mg,94.5 mg /0.5 mL Inj Sol-0.5 mL Vial Pk,Yes,1106.918028,1106.918028,FULLY REIMBURSABLE,1106.918028,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-07-08,,02530740,Livtencity,200 mg,Tab,$276.7857,276.7857,,200 mg Tab,No,298.928556,298.928556,FULLY REIMBURSABLE,298.928556,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-05-31,,02485559,Renvela,0.8g,Pd for Susp,$1.3127/Sachet,1.3127,Sachet,0.8g Pd for Susp,No,1.417716,1.417716,FULLY REIMBURSABLE,1.417716,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-05-31,,02485567,Renvela,2.4g,Pd for Susp,$3.9380/Sachet,3.938,Sachet,2.4g Pd for Susp,No,4.25304,4.25304,FULLY REIMBURSABLE,4.25304,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-05-15,,02533294,Empaveli,54 mg / mL,Inj Sol-20 mL Vial,$4970.0000/Vial,4970.0,Vial,54 mg / mL Inj Sol-20 mL Vial,No,5367.6,5367.6,FULLY REIMBURSABLE,5367.6,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02513099,Braftovi,75 mg,Cap,$52.7625,52.7625,,75 mg Cap,No,56.9835,56.9835,FULLY REIMBURSABLE,56.9835,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02398958,Diacomit,250 mg,Cap,$6.4806,6.4806,,250 mg Cap,No,6.999048,6.999048,FULLY REIMBURSABLE,6.999048,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02398974,Diacomit,250 mg /Pk,Pd for Oral Susp,$6.4806,6.4806,,250 mg /Pk Pd for Oral Susp,Yes,6.999048,6.999048,FULLY REIMBURSABLE,6.999048,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02398966,Diacomit,500 mg,Cap,$12.9408,12.9408,,500 mg Cap,No,13.976064,13.976064,FULLY REIMBURSABLE,13.976064,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02401703,Genotropin GoQuick,5.3 mg powder for solution,Pre-filled pen,$159.0700,159.07,,5.3 mg powder for solution Pre-filled pen,No,171.7956,171.7956,FULLY REIMBURSABLE,171.7956,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02401711,Genotropin GoQuick,12 mg powder for solution,Pre-filled pen,$360.1400,360.14,,12 mg powder for solution Pre-filled pen,No,388.9512,388.9512,FULLY REIMBURSABLE,388.9512,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02401762,Genotropin MiniQuick,0.6 mg powder for solution,Prefilled syringe,$18.0100,18.01,,0.6 mg powder for solution Prefilled syringe,No,19.4508,19.4508,FULLY REIMBURSABLE,19.4508,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02401770,Genotropin MiniQuick,0.8 mg powder for solution,Prefilled syringe,$24.0100,24.01,,0.8 mg powder for solution Prefilled syringe,No,25.9308,25.9308,FULLY REIMBURSABLE,25.9308,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02401789,Genotropin MiniQuick,1.0 mg powder for solution,Prefilled syringe,$30.0100,30.01,,1.0 mg powder for solution Prefilled syringe,No,32.4108,32.4108,FULLY REIMBURSABLE,32.4108,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02401797,Genotropin MiniQuick,1.2 mg powder for solution,Prefilled syringe,$36.0200,36.02,,1.2 mg powder for solution Prefilled syringe,No,38.9016,38.9016,FULLY REIMBURSABLE,38.9016,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02401800,Genotropin MiniQuick,1.4 mg powder for solution,Prefilled syringe,$42.0200,42.02,,1.4 mg powder for solution Prefilled syringe,No,45.3816,45.3816,FULLY REIMBURSABLE,45.3816,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02401819,Genotropin MiniQuick,1.6 mg powder for solution,Prefilled syringe,$48.0200,48.02,,1.6 mg powder for solution Prefilled syringe,No,51.8616,51.8616,FULLY REIMBURSABLE,51.8616,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02401827,Genotropin MiniQuick,1.8 mg powder for solution,Prefilled syringe,$54.0200,54.02,,1.8 mg powder for solution Prefilled syringe,No,58.3416,58.3416,FULLY REIMBURSABLE,58.3416,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02401835,Genotropin MiniQuick,2.0 mg powder for solution,Prefilled syringe,$60.0200,60.02,,2.0 mg powder for solution Prefilled syringe,No,64.8216,64.8216,FULLY REIMBURSABLE,64.8216,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02434814,Jakavi,10 mg,Tab,$97.1600,97.16,,10 mg Tab,No,104.9328,104.9328,FULLY REIMBURSABLE,104.9328,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02388014,Jakavi,15 mg,Tab,$97.1600,97.16,,15 mg Tab,No,104.9328,104.9328,FULLY REIMBURSABLE,104.9328,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02388022,Jakavi,20 mg,Tab,$97.1600,97.16,,20 mg Tab,No,104.9328,104.9328,FULLY REIMBURSABLE,104.9328,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02511355,Kesimpta,20 mg /0.4 mL,Inj Sol-0.4 mL Pref SensoReady Pen Pk,$2318.7400,2318.74,,20 mg /0.4 mL Inj Sol-0.4 mL Pref SensoReady Pen Pk,Yes,2504.2392,2504.2392,FULLY REIMBURSABLE,2504.2392,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02473569,Kisqali,200 mg,Tab,$94.1271,94.1271,,200 mg Tab,No,101.657268,101.657268,FULLY REIMBURSABLE,101.657268,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02409658,Mekinist,2 mg,Tab,$342.1270,342.127,,2 mg Tab,No,369.49716,369.49716,FULLY REIMBURSABLE,369.49716,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02513080,Mektovi,15 mg,Tab,$38.3250,38.325,,15 mg Tab,No,41.391,41.391,FULLY REIMBURSABLE,41.391,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02449781,Nucala,100 mg / mL,Inj Pd-Vial Pk,$2318.1300,2318.13,,100 mg / mL Inj Pd-Vial Pk,Yes,2503.5804,2503.5804,FULLY REIMBURSABLE,2503.5804,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02532611,Radicava,105 mg /5 mL,Oral Susp,$189.5200/ mL,189.52,mL,105 mg /5 mL Oral Susp,No,204.6816,204.6816,FULLY REIMBURSABLE,204.6816,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,01902644,Retrovir,10 mg / mL,Inj Sol,$1.0182/ mL,1.0182,mL,10 mg / mL Inj Sol,No,1.099656,1.099656,FULLY REIMBURSABLE,1.099656,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,01902652,Retrovir,50 mg /5 mL,Syrup,$0.2423/ mL,0.2423,mL,50 mg /5 mL Syrup,No,0.261684,0.261684,FULLY REIMBURSABLE,0.261684,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02522845,Saphnelo,150 mg / mL,Inj Sol-2 mL Vial Pk (Preservative-Free),$1736.1391/Vial,1736.1391,Vial,150 mg / mL Inj Sol-2 mL Vial Pk (Preservative-Free),Yes,1875.030228,1875.030228,FULLY REIMBURSABLE,1875.030228,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02456214,Tagrisso,40 mg,Tab,$322.1280,322.128,,40 mg Tab,No,347.89824,347.89824,FULLY REIMBURSABLE,347.89824,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-30,,02456222,Tagrisso,80 mg,Tab,$322.1280,322.128,,80 mg Tab,No,347.89824,347.89824,FULLY REIMBURSABLE,347.89824,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-17,,02370050,Benlysta,120 mg /Vial,Pd for Sol-5 mL Vial (Preservative-Free),$305.7100/Vial,305.71,Vial,120 mg /Vial Pd for Sol-5 mL Vial (Preservative-Free),No,330.1668,330.1668,FULLY REIMBURSABLE,330.1668,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-17,,02370069,Benlysta,400 mg /Vial,Pd for Sol-20 mL Vial (Preservative-Free),$1019.0100/Vial,1019.01,Vial,400 mg /Vial Pd for Sol-20 mL Vial (Preservative-Free),No,1100.5308,1100.5308,FULLY REIMBURSABLE,1100.5308,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-16,,02540185,Erleada,240 mg,Tab,$124.5600,124.56,,240 mg Tab,No,134.5248,134.5248,FULLY REIMBURSABLE,134.5248,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-12,,02532107,Skyrizi,60 mg / mL,Inj Sol-10 mL Vial (Preservative-Free),$4593.1400/Vial,4593.14,Vial,60 mg / mL Inj Sol-10 mL Vial (Preservative-Free),No,4960.5912,4960.5912,FULLY REIMBURSABLE,4960.5912,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-12,,02532093,Skyrizi,360 mg /2.4 mL,Inj Sol-2.4 mL Pref Cart (Preservative-Free),$4593.1400/Cart,4593.14,Cart,360 mg /2.4 mL Inj Sol-2.4 mL Pref Cart (Preservative-Free),No,4960.5912,4960.5912,FULLY REIMBURSABLE,4960.5912,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-10,,02506009,Zeposia,0.23 mg & 0.46 mg,Caps (Starter Kit Pk),$547.9432/Kit Pk,547.9432,Kit Pk,0.23 mg & 0.46 mg Caps (Starter Kit Pk),Yes,591.778656,591.778656,FULLY REIMBURSABLE,591.778656,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-04-10,,02505991,Zeposia,0.92 mg,Cap,$68.4932,68.4932,,0.92 mg Cap,No,73.972656,73.972656,FULLY REIMBURSABLE,73.972656,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-03-28,,02350092,Actemra,80 mg /4 mL,Inj Sol-Vial Pk,$191.9400,191.94,,80 mg /4 mL Inj Sol-Vial Pk,Yes,207.2952,207.2952,FULLY REIMBURSABLE,207.2952,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-03-28,,02483327,Actemra,162 mg /0.9 mL,Auto-Injector (Preservative-Free),$372.7500/Auto-Injector,372.75,Auto-Injector,162 mg /0.9 mL Auto-Injector (Preservative-Free),No,402.57,402.57,FULLY REIMBURSABLE,402.57,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-03-28,,02424770,Actemra,162 mg /0.9 mL,Inj Sol-Pref Syr,$376.8500,376.85,,162 mg /0.9 mL Inj Sol-Pref Syr,No,406.998,406.998,FULLY REIMBURSABLE,406.998,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-03-28,,02350106,Actemra,200 mg /10 mL,Inj Sol-Vial Pk,$479.8500,479.85,,200 mg /10 mL Inj Sol-Vial Pk,Yes,518.238,518.238,FULLY REIMBURSABLE,518.238,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-03-28,,02350114,Actemra,400 mg /20 mL,Inj Sol-Vial Pk,$959.7000,959.7,,400 mg /20 mL Inj Sol-Vial Pk,Yes,1036.476,1036.476,FULLY REIMBURSABLE,1036.476,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-03-28,,02273322,Aptivus,250 mg,Cap,$9.6945,9.6945,,250 mg Cap,No,10.47006,10.47006,FULLY REIMBURSABLE,10.47006,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-03-28,,02452340,Cotellic,20 mg,Tab,$131.3576,131.3576,,20 mg Tab,No,141.866208,141.866208,FULLY REIMBURSABLE,141.866208,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-03-01,,02491559,Ultomiris,10 mg / mL,Inj Sol-Vial,$242.7383/ mL,242.7383,mL,10 mg / mL Inj Sol-Vial,No,262.157364,262.157364,FULLY REIMBURSABLE,262.157364,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-03-01,,02533448,Ultomiris,100 mg / mL,Inj Sol-Vial,"$2,427.3833/ mL",2427.3833,mL,100 mg / mL Inj Sol-Vial,No,2621.573964,2621.573964,FULLY REIMBURSABLE,2621.573964,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-03-01,,02533456,Ultomiris,100 mg / mL,Inj Sol-Vial,"$2,427.3818/ mL",2427.3818,mL,100 mg / mL Inj Sol-Vial,No,2621.572344,2621.572344,FULLY REIMBURSABLE,2621.572344,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-02-07,,02536579,Ferriprox MR,1000 mg,MR Tab,$33.4740,33.474,,1000 mg MR Tab,No,36.15192,36.15192,FULLY REIMBURSABLE,36.15192,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-01-31,,02298791,Emend,80 mg,Cap,$35.6613,35.6613,,80 mg Cap,No,38.514204,38.514204,FULLY REIMBURSABLE,38.514204,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-01-31,,02298805,Emend,125 mg,Cap,$35.3274,35.3274,,125 mg Cap,No,38.153592,38.153592,FULLY REIMBURSABLE,38.153592,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-01-31,,02451158,Uptravi,200mcg,Tab,$74.7550,74.755,,200mcg Tab,No,80.7354,80.7354,FULLY REIMBURSABLE,80.7354,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-01-31,,02451166,Uptravi,400mcg,Tab,$74.7550,74.755,,400mcg Tab,No,80.7354,80.7354,FULLY REIMBURSABLE,80.7354,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-01-31,,02451174,Uptravi,600mcg,Tab,$74.7550,74.755,,600mcg Tab,No,80.7354,80.7354,FULLY REIMBURSABLE,80.7354,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-01-31,,02451182,Uptravi,800mcg,Tab,$74.7550,74.755,,800mcg Tab,No,80.7354,80.7354,FULLY REIMBURSABLE,80.7354,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-01-31,,02451190,Uptravi,1000mcg,Tab,$74.7550,74.755,,1000mcg Tab,No,80.7354,80.7354,FULLY REIMBURSABLE,80.7354,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-01-31,,02451204,Uptravi,1200mcg,Tab,$74.7550,74.755,,1200mcg Tab,No,80.7354,80.7354,FULLY REIMBURSABLE,80.7354,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-01-31,,02451212,Uptravi,1400mcg,Tab,$74.7550,74.755,,1400mcg Tab,No,80.7354,80.7354,FULLY REIMBURSABLE,80.7354,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-01-31,,02451220,Uptravi,1600mcg,Tab,$74.7550,74.755,,1600mcg Tab,No,80.7354,80.7354,FULLY REIMBURSABLE,80.7354,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2024-01-31,,02368153,Xgeva,120 mg /1.7 mL,Inj Sol-Vial Pk,$715.2100,715.21,,120 mg /1.7 mL Inj Sol-Vial Pk,Yes,772.4268,772.4268,FULLY REIMBURSABLE,772.4268,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-12-21,,02542285,Trikafta,80 mg /40 mg /60 mg & 59.5 mg,Gran (Packet),$420.0000/ Packet,420.0,Packet,80 mg /40 mg /60 mg & 59.5 mg Gran (Packet),No,453.6,453.6,FULLY REIMBURSABLE,453.6,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-12-21,,02542277,Trikafta,100 mg /50 mg /75 mg & 75 mg,Gran (Packet),$420.0000/ Packet,420.0,Packet,100 mg /50 mg /75 mg & 75 mg Gran (Packet),No,453.6,453.6,FULLY REIMBURSABLE,453.6,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-12-11,,02533979,Qulipta,10 mg,Tab,$18.4400,18.44,,10 mg Tab,No,19.9152,19.9152,FULLY REIMBURSABLE,19.9152,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-12-11,,02533987,Qulipta,30 mg,Tab,$18.4400,18.44,,30 mg Tab,No,19.9152,19.9152,FULLY REIMBURSABLE,19.9152,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-12-11,,02533995,Qulipta,60 mg,Tab,$18.4400,18.44,,60 mg Tab,No,19.9152,19.9152,FULLY REIMBURSABLE,19.9152,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-10-31,,02499827,Tukysa,50 mg,Tab,$35.4947,35.4947,,50 mg Tab,No,38.334276,38.334276,FULLY REIMBURSABLE,38.334276,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-10-31,,02499835,Tukysa,150 mg,Tab,$106.4843,106.4843,,150 mg Tab,No,115.003044,115.003044,FULLY REIMBURSABLE,115.003044,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-10-30,,02459787,Xolair,75 mg /0.5 mL,Inj Sol-0.5 mL Pref Syr (Preservative-Free),$281.2400/Pref Syr,281.24,Pref Syr,75 mg /0.5 mL Inj Sol-0.5 mL Pref Syr (Preservative-Free),No,303.7392,303.7392,FULLY REIMBURSABLE,303.7392,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-10-03,,02528363,Cibinqo,50 mg,Tab,$48.6667,48.6667,,50 mg Tab,No,52.560036,52.560036,FULLY REIMBURSABLE,52.560036,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-10-03,,02528371,Cibinqo,100 mg,Tab,$48.6667,48.6667,,100 mg Tab,No,52.560036,52.560036,FULLY REIMBURSABLE,52.560036,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-10-03,,02528398,Cibinqo,200 mg,Tab,$54.4667,54.4667,,200 mg Tab,No,58.824036,58.824036,FULLY REIMBURSABLE,58.824036,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-09-27,,02530031,Zejula,100 mg,Tab,$133.2346,133.2346,,100 mg Tab,No,143.893368,143.893368,FULLY REIMBURSABLE,143.893368,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-09-07,,02506343,Givlaari,189 mg/ mL,Inj Sol-Vial Pk (Preservative-Free),$341.0280/ mg,341.028,mg,189 mg/ mL Inj Sol-Vial Pk (Preservative-Free),Yes,368.31024,368.31024,FULLY REIMBURSABLE,368.31024,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-09-07,,02527677,Xpovio,20 mg,Tab,$550.0000,550.0,,20 mg Tab,No,594.0,594.0,FULLY REIMBURSABLE,594.0,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-08-10,,02535696,Calquence,100 mg,Tab,$142.7738,142.7738,,100 mg Tab,No,154.195704,154.195704,FULLY REIMBURSABLE,154.195704,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-08-02,,02502984,Firdapse,10 mg,Tab,$18.0000,18.0,,10 mg Tab,No,19.44,19.44,FULLY REIMBURSABLE,19.44,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-07-17,,02485966,Lorbrena,25 mg,Tab,$112.4443,112.4443,,25 mg Tab,No,121.439844,121.439844,FULLY REIMBURSABLE,121.439844,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-07-17,,02485974,Lorbrena,100 mg,Tab,$337.3333,337.3333,,100 mg Tab,No,364.319964,364.319964,FULLY REIMBURSABLE,364.319964,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-07-12,,02529181,Norditropin FlexPro,5 mg/1.5 mL,Inj Sol-1.5 mL Pref Pen,$194.7000,194.7,,5 mg/1.5 mL Inj Sol-1.5 mL Pref Pen,No,210.276,210.276,FULLY REIMBURSABLE,210.276,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-07-12,,02529203,Norditropin FlexPro,10 mg/1.5 mL,Inj Sol-1.5 mL Pref Pen,$389.4000,389.4,,10 mg/1.5 mL Inj Sol-1.5 mL Pref Pen,No,420.552,420.552,FULLY REIMBURSABLE,420.552,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-07-12,,02529211,Norditropin FlexPro,15 mg/1.5 mL,Inj Sol-1.5 mL Pref Pen,$584.1000,584.1,,15 mg/1.5 mL Inj Sol-1.5 mL Pref Pen,No,630.828,630.828,FULLY REIMBURSABLE,630.828,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-06-22,,02527707,Albrioza,3 g & 1 g,Pd for Oral Susp,$306.7123/Sachet,306.7123,Sachet,3 g & 1 g Pd for Oral Susp,No,331.249284,331.249284,FULLY REIMBURSABLE,331.249284,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-05-26,,02509733,Increlex,10 mg/ mL,Inj Sol-4 mL Vial (With Preservative),$5916.6400/Vial,5916.64,Vial,10 mg/ mL Inj Sol-4 mL Vial (With Preservative),No,6389.9712,6389.9712,FULLY REIMBURSABLE,6389.9712,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-05-19,,02528320,Scemblix,20 mg,Tab,$63.0000,63.0,,20 mg Tab,No,68.04,68.04,FULLY REIMBURSABLE,68.04,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-05-19,,02528339,Scemblix,40 mg,Tab,$85.0000,85.0,,40 mg Tab,No,91.8,91.8,FULLY REIMBURSABLE,91.8,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-05-15,,02521679,Ngenla,24 mg/1.2 mL,Inj Sol-1.2 mL Pref Pen (With Preservative),$345.8400,345.84,,24 mg/1.2 mL Inj Sol-1.2 mL Pref Pen (With Preservative),No,373.5072,373.5072,FULLY REIMBURSABLE,373.5072,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-05-15,,02521687,Ngenla,60 mg/1.2 mL,Inj Sol-1.2 mL Pref Pen (With Preservative),$864.6000,864.6,,60 mg/1.2 mL Inj Sol-1.2 mL Pref Pen (With Preservative),No,933.768,933.768,FULLY REIMBURSABLE,933.768,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-04-28,,02509474,Ajovy,225 mg /1.5 mL,Inj Sol-1.5 mL Pref Autoinj Pk (Preservative-Free),$560.9800,560.98,,225 mg /1.5 mL Inj Sol-1.5 mL Pref Autoinj Pk (Preservative-Free),Yes,605.8584,605.8584,FULLY REIMBURSABLE,605.8584,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-04-28,,02497859,Ajovy,225 mg /1.5 mL,Inj Sol-1.5 mL Pref Syr Pk (Preservative-Free),$560.9800,560.98,,225 mg /1.5 mL Inj Sol-1.5 mL Pref Syr Pk (Preservative-Free),Yes,605.8584,605.8584,FULLY REIMBURSABLE,605.8584,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-04-28,,02491788,Calquence,100 mg,Cap,$142.7738,142.7738,,100 mg Cap,No,154.195704,154.195704,FULLY REIMBURSABLE,154.195704,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-04-28,,02478374,Erleada,60 mg,Tab,$31.1400,31.14,,60 mg Tab,No,33.6312,33.6312,FULLY REIMBURSABLE,33.6312,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-04-28,,02473232,Fasenra,30 mg / mL,Inj Sol-Pref Syr (Preservative Free),$4115.5400,4115.54,,30 mg / mL Inj Sol-Pref Syr (Preservative Free),No,4444.7832,4444.7832,FULLY REIMBURSABLE,4444.7832,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-04-28,,02496135,Fasenra Pen,30 mg / mL,Inj Sol-1 mL Pref Autoinj (Preservative-Free),$4036.8000,4036.8,,30 mg / mL Inj Sol-1 mL Pref Autoinj (Preservative-Free),No,4359.744,4359.744,FULLY REIMBURSABLE,4359.744,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-04-28,,02389630,Inlyta,1 mg,Tab,$20.5073,20.5073,,1 mg Tab,No,22.147884,22.147884,FULLY REIMBURSABLE,22.147884,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-04-28,,02389649,Inlyta,5 mg,Tab,$102.5387,102.5387,,5 mg Tab,No,110.741796,110.741796,FULLY REIMBURSABLE,110.741796,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-04-28,,02475200,Lynparza,100 mg,Tab,$69.9482,69.9482,,100 mg Tab,No,75.544056,75.544056,FULLY REIMBURSABLE,75.544056,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-04-28,,02475219,Lynparza,150 mg,Tab,$69.9482,69.9482,,150 mg Tab,No,75.544056,75.544056,FULLY REIMBURSABLE,75.544056,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-04-28,,02463121,Ocaliva,5 mg,Tab,$108.4110,108.411,,5 mg Tab,No,117.08388,117.08388,FULLY REIMBURSABLE,117.08388,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-04-28,,02463148,Ocaliva,10 mg,Tab,$108.4110,108.411,,10 mg Tab,No,117.08388,117.08388,FULLY REIMBURSABLE,117.08388,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-04-28,,02445727,Revestive,5 mg Vial,Pd for Inj-Vial Pk,$925.0000/ Vial,925.0,Vial,5 mg Vial Pd for Inj-Vial Pk,Yes,999.0,999.0,FULLY REIMBURSABLE,999.0,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-03-31,,09857395,Avonex Pen,30 mcg /0.5 mL,Pref AutoInj Pen,$491.2525,491.2525,,30 mcg /0.5 mL Pref AutoInj Pen,No,530.5527,530.5527,FULLY REIMBURSABLE,530.5527,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-03-31,,02269201,Avonex PS,30 mcg /0.5 mL,Pref Syr,$491.2525,491.2525,,30 mcg /0.5 mL Pref Syr,No,530.5527,530.5527,FULLY REIMBURSABLE,530.5527,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-03-31,,02501600,Inqovi,35 mg & 100 mg,Tab,$1172.0000,1172.0,,35 mg & 100 mg Tab,No,1265.76,1265.76,FULLY REIMBURSABLE,1265.76,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-03-31,,02245913,Kineret,150 mg / mL Inj,Pref Syr-0.67 mL Pk,$54.6182,54.6182,,150 mg / mL Inj Pref Syr-0.67 mL Pk,Yes,58.987656,58.987656,FULLY REIMBURSABLE,58.987656,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-03-31,,02177757,M-Eslon,200 mg,ER Cap,$4.5151,4.5151,,200 mg ER Cap,No,4.876308,4.876308,FULLY REIMBURSABLE,4.876308,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-03-31,,02444402,Plegridy,63 mcg /0.5 mL & 94 mcg /0.5 mL,Pref Syr-Kit Pk,$1879.4900,1879.49,,63 mcg /0.5 mL & 94 mcg /0.5 mL Pref Syr-Kit Pk,Yes,2029.8492,2029.8492,FULLY REIMBURSABLE,2029.8492,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-03-31,,02444399,Plegridy,125 mcg /0.5 mL,Inj Sol-2 Pref Syr Pk,$1879.4900/Pk,1879.49,Pk,125 mcg /0.5 mL Inj Sol-2 Pref Syr Pk,Yes,2029.8492,2029.8492,FULLY REIMBURSABLE,2029.8492,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-03-31,,09857557,Plegridy,63 mcg /0.5 mL & 94 mcg /0.5 mL,Pref Pen-Kit Pk,$1879.4900,1879.49,,63 mcg /0.5 mL & 94 mcg /0.5 mL Pref Pen-Kit Pk,Yes,2029.8492,2029.8492,FULLY REIMBURSABLE,2029.8492,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-03-31,,09857556,Plegridy,125 mcg /0.5 mL,Inj Sol-2 Pref Pen Pk,$1879.4900/Pk,1879.49,Pk,125 mcg /0.5 mL Inj Sol-2 Pref Pen Pk,Yes,2029.8492,2029.8492,FULLY REIMBURSABLE,2029.8492,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-03-09,,02512963,Brukinsa,80 mg,Cap,$67.9833,67.9833,,80 mg Cap,No,73.421964,73.421964,FULLY REIMBURSABLE,73.421964,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-02-27,,02505541,Reblozyl,25 mg /Vial,Pd for Sol-Vial Pk (Preservative-Free),$2189.0000/Vial,2189.0,Vial,25 mg /Vial Pd for Sol-Vial Pk (Preservative-Free),Yes,2364.12,2364.12,FULLY REIMBURSABLE,2364.12,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-02-27,,02505568,Reblozyl,75 mg /Vial,Pd for Sol-Vial Pk (Preservative-Free),$6567.0000/Vial,6567.0,Vial,75 mg /Vial Pd for Sol-Vial Pk (Preservative-Free),Yes,7092.36,7092.36,FULLY REIMBURSABLE,7092.36,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-02-24,,02490315,Vitrakvi,25 mg,Cap,$52.3375,52.3375,,25 mg Cap,No,56.5245,56.5245,FULLY REIMBURSABLE,56.5245,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-02-24,,02490323,Vitrakvi,100 mg,Cap,$209.3500,209.35,,100 mg Cap,No,226.098,226.098,FULLY REIMBURSABLE,226.098,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-02-24,,02490331,Vitrakvi,20 mg / mL,Oral Sol-100 mL Bottle Pk,$4187.0000/Pk,4187.0,Pk,20 mg / mL Oral Sol-100 mL Bottle Pk,Yes,4521.96,4521.96,FULLY REIMBURSABLE,4521.96,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2023-02-03,,02499681,Enspryng,120 mg / mL,Inj Sol-Pref Syr (Preservative-Free),$9450.0000/Pref Syr,9450.0,Pref Syr,120 mg / mL Inj Sol-Pref Syr (Preservative-Free),No,10206.0,10206.0,FULLY REIMBURSABLE,10206.0,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-12-01,,02524252,Dupixent,200 mg /1.14 mL,Inj Sol-1.14 mL Pref Pen (Preservative-Free),$978.7000,978.7,,200 mg /1.14 mL Inj Sol-1.14 mL Pref Pen (Preservative-Free),No,1056.996,1056.996,FULLY REIMBURSABLE,1056.996,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-11-14,,02510197,Onureg,200 mg,Tab,$952.0000,952.0,,200 mg Tab,No,1028.16,1028.16,FULLY REIMBURSABLE,1028.16,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-11-14,,02510200,Onureg,300 mg,Tab,$1428.0000,1428.0,,300 mg Tab,No,1542.24,1542.24,FULLY REIMBURSABLE,1542.24,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-09-15,,02517841,Vyndamax,61 mg,Cap,$534.2800,534.28,,61 mg Cap,No,577.0224,577.0224,FULLY REIMBURSABLE,577.0224,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-09-08,,02502445,Inrebic,100 mg,Cap,$84.3930,84.393,,100 mg Cap,No,91.14444,91.14444,FULLY REIMBURSABLE,91.14444,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-08-11,,02515067,Waymade-Trientine,250 mg,Cap,$20.0000,20.0,,250 mg Cap,No,21.6,21.6,FULLY REIMBURSABLE,21.6,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-08-15,,02500264,Kynmobi,10 mg,Soluble Film,$9.5400,9.54,,10 mg Soluble Film,No,10.3032,10.3032,FULLY REIMBURSABLE,10.3032,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-08-15,,02500272,Kynmobi,15 mg,Soluble Film,$9.5400,9.54,,15 mg Soluble Film,No,10.3032,10.3032,FULLY REIMBURSABLE,10.3032,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-08-15,,02500280,Kynmobi,20 mg,Soluble Film,$9.5400,9.54,,20 mg Soluble Film,No,10.3032,10.3032,FULLY REIMBURSABLE,10.3032,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-08-15,,02500299,Kynmobi,25 mg,Soluble Film,$9.5400,9.54,,25 mg Soluble Film,No,10.3032,10.3032,FULLY REIMBURSABLE,10.3032,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-08-15,,02500302,Kynmobi,30 mg,Soluble Film,$9.5400,9.54,,30 mg Soluble Film,No,10.3032,10.3032,FULLY REIMBURSABLE,10.3032,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-08-04,,02483629,Crysvita,10 mg / mL,Inj Sol-Vial,$451.4940/ mg,451.494,mg,10 mg / mL Inj Sol-Vial,No,487.61352,487.61352,FULLY REIMBURSABLE,487.61352,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-08-04,,02483637,Crysvita,20 mg / mL,Inj Sol-Vial,$451.4950/ mg,451.495,mg,20 mg / mL Inj Sol-Vial,No,487.6146,487.6146,FULLY REIMBURSABLE,487.6146,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-08-04,,02483645,Crysvita,30 mg / mL,Inj Sol-Vial,$451.4947/ mg,451.4947,mg,30 mg / mL Inj Sol-Vial,No,487.614276,487.614276,FULLY REIMBURSABLE,487.614276,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-07-21,,02495244,Vascepa,1 g,Cap,$2.4500,2.45,,1 g Cap,No,2.646,2.646,FULLY REIMBURSABLE,2.646,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-07-08,,02526670,Trikafta,50 mg /25 mg /37.5 mg & 75 mg,Tab,$280.0000/Tab,280.0,Tab,50 mg /25 mg /37.5 mg & 75 mg Tab,No,302.4,302.4,FULLY REIMBURSABLE,302.4,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-05-31,,02474263,Humira,20 mg /0.2 mL,Inj Sol-Pref Syr Pk,$397.0500,397.05,,20 mg /0.2 mL Inj Sol-Pref Syr Pk,Yes,428.814,428.814,FULLY REIMBURSABLE,428.814,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-05-31,,09854785,Humira (Pediatric),40 mg /0.8 mL,Inj Sol-Vial Pk,$794.1000,794.1,,40 mg /0.8 mL Inj Sol-Vial Pk,Yes,857.628,857.628,FULLY REIMBURSABLE,857.628,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-05-06,,02458039,Venclexta,10 mg,Tab,$7.0800,7.08,,10 mg Tab,No,7.6464,7.6464,FULLY REIMBURSABLE,7.6464,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-05-06,,02458047,Venclexta,50 mg,Tab,$35.4000,35.4,,50 mg Tab,No,38.232,38.232,FULLY REIMBURSABLE,38.232,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-05-06,,02458055,Venclexta,100 mg,Tab,$70.8000,70.8,,100 mg Tab,No,76.464,76.464,FULLY REIMBURSABLE,76.464,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-05-06,,02458063,Venclexta,10 mg & 50 mg & 100 mg,Tabs (Starter Kit Pk),$1833.7200/Kit Pk,1833.72,Kit Pk,10 mg & 50 mg & 100 mg Tabs (Starter Kit Pk),Yes,1980.4176,1980.4176,FULLY REIMBURSABLE,1980.4176,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-04-29,,02480824,Cabometyx,20 mg,Tab,$301.2944,301.2944,,20 mg Tab,No,325.397952,325.397952,FULLY REIMBURSABLE,325.397952,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-04-29,,02480832,Cabometyx,40 mg,Tab,$301.2944,301.2944,,40 mg Tab,No,325.397952,325.397952,FULLY REIMBURSABLE,325.397952,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-04-29,,02480840,Cabometyx,60 mg,Tab,$301.2944,301.2944,,60 mg Tab,No,325.397952,325.397952,FULLY REIMBURSABLE,325.397952,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-04-29,,02472961,Kevzara,131.6 mg / mL,Inj Sol-Pref Pen,$745.6900,745.69,,131.6 mg / mL Inj Sol-Pref Pen,No,805.3452,805.3452,FULLY REIMBURSABLE,805.3452,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-04-29,,02472988,Kevzara,175.0 mg / mL,Inj Sol-Pref Pen,$745.6900,745.69,,175.0 mg / mL Inj Sol-Pref Pen,No,805.3452,805.3452,FULLY REIMBURSABLE,805.3452,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-04-29,,02460548,Kevzara,175.0 mg / mL,Inj Sol-Pref Syr,$745.6900,745.69,,175.0 mg / mL Inj Sol-Pref Syr,No,805.3452,805.3452,FULLY REIMBURSABLE,805.3452,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-04-29,,02322854,Nplate,250 mcg /0.5 mL,Pd for Inj-Vial Pk,$1033.0200,1033.02,,250 mcg /0.5 mL Pd for Inj-Vial Pk,Yes,1115.6616,1115.6616,FULLY REIMBURSABLE,1115.6616,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-04-29,,02322862,Nplate,500 mcg /1 mL,Pd for Inj-Vial Pk,$2066.0700,2066.07,,500 mcg /1 mL Pd for Inj-Vial Pk,Yes,2231.3556,2231.3556,FULLY REIMBURSABLE,2231.3556,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-04-29,,02372525,OxyNEO,10 mg,CR Tab,$0.9850,0.985,,10 mg CR Tab,No,1.0638,1.0638,FULLY REIMBURSABLE,1.0638,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-04-29,,02372533,OxyNEO,15 mg,CR Tab,$1.1905,1.1905,,15 mg CR Tab,No,1.28574,1.28574,FULLY REIMBURSABLE,1.28574,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-04-29,,02372797,OxyNEO,20 mg,CR Tab,$1.4770,1.477,,20 mg CR Tab,No,1.59516,1.59516,FULLY REIMBURSABLE,1.59516,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-04-29,,02372541,OxyNEO,30 mg,CR Tab,$1.9555,1.9555,,30 mg CR Tab,No,2.11194,2.11194,FULLY REIMBURSABLE,2.11194,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-04-29,,02372568,OxyNEO,40 mg,CR Tab,$2.5515,2.5515,,40 mg CR Tab,No,2.75562,2.75562,FULLY REIMBURSABLE,2.75562,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-04-29,,02384256,Xalkori,200 mg,Tab,$131.4300,131.43,,200 mg Tab,No,141.9444,141.9444,FULLY REIMBURSABLE,141.9444,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-04-29,,02384264,Xalkori,250 mg,Tab,$131.4300,131.43,,250 mg Tab,No,141.9444,141.9444,FULLY REIMBURSABLE,141.9444,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-04-29,,02489783,Zejula,100 mg,Cap,$133.2346,133.2346,,100 mg Cap,No,143.893368,143.893368,FULLY REIMBURSABLE,143.893368,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-03-28,,02514931,Evrysdi,0.75 mg / mL,Pd for Oral Sol,$193.9725/ mg,193.9725,mg,0.75 mg / mL Pd for Oral Sol,No,209.4903,209.4903,FULLY REIMBURSABLE,209.4903,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-03-25,,02504855,MAR-Trientine,250 mg,Cap,$20.0000,20.0,,250 mg Cap,No,21.6,21.6,FULLY REIMBURSABLE,21.6,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-03-25,,02496429,Mayzent,0.25 mg,Tab,$22.3285,22.3285,,0.25 mg Tab,No,24.11478,24.11478,FULLY REIMBURSABLE,24.11478,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-03-25,,02496437,Mayzent,2 mg,Tab,$89.3150,89.315,,2 mg Tab,No,96.4602,96.4602,FULLY REIMBURSABLE,96.4602,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-02-10,,02479206,Alunbrig,30 mg,Tab,$112.3214,112.3214,,30 mg Tab,No,121.307112,121.307112,FULLY REIMBURSABLE,121.307112,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-02-10,,02479214,Alunbrig,90 mg,Tab,$336.9643,336.9643,,90 mg Tab,No,363.921444,363.921444,FULLY REIMBURSABLE,363.921444,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-02-10,,02479222,Alunbrig,180 mg,Tab,$336.9643,336.9643,,180 mg Tab,No,363.921444,363.921444,FULLY REIMBURSABLE,363.921444,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-02-10,,02479230,Alunbrig,90 mg & 180 mg,Tabs (Starter Kit Pk),$9435.0000/Kit Pk,9435.0,Kit Pk,90 mg & 180 mg Tabs (Starter Kit Pk),Yes,10189.8,10189.8,FULLY REIMBURSABLE,10189.8,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2022-01-14,,02505614,Takhzyro,300 mg /2 mL,Inj Sol-Pref Syr (Preservative-Free),$68.4600/ mg,68.46,mg,300 mg /2 mL Inj Sol-Pref Syr (Preservative-Free),No,73.9368,73.9368,FULLY REIMBURSABLE,73.9368,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-12-03,,02510049,Dupixent,150 mg / mL,Inj Sol-2 mL Pref Pen Pk,$978.7000,978.7,,150 mg / mL Inj Sol-2 mL Pref Pen Pk,Yes,1056.996,1056.996,FULLY REIMBURSABLE,1056.996,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-11-23,,02459795,Xolair,150 mg / mL,Inj Sol-1 mL Pref Syr Pk,$641.6000,641.6,,150 mg / mL Inj Sol-1 mL Pref Syr Pk,Yes,692.928,692.928,FULLY REIMBURSABLE,692.928,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-10-29,,02509695,Zolgensma,2 × 1013 VG/ mL,Inj Sol-Vial Combi Pk,"$2,910,500.0000",2910500.0,,2 × 1013 VG/ mL Inj Sol-Vial Combi Pk,Yes,3143340.0,3143340.0,FULLY REIMBURSABLE,3143340.0,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-09-22,,02517140,Trikafta,100 mg /50 mg /75 mg & 150 mg,Tab,$280.0000/Tab,280.0,Tab,100 mg /50 mg /75 mg & 150 mg Tab,No,302.4,302.4,FULLY REIMBURSABLE,302.4,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-06-25,,02463040,Orkambi,125 mg /100 mg,Tab,$170.5357,170.5357,,125 mg /100 mg Tab,No,184.178556,184.178556,FULLY REIMBURSABLE,184.178556,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-06-25,,02451379,Orkambi,125 mg /200 mg,Tab,$170.5357,170.5357,,125 mg /200 mg Tab,No,184.178556,184.178556,FULLY REIMBURSABLE,184.178556,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-06-08,,02496348,Nubeqa,300 mg,Tab,$28.3440,28.344,,300 mg Tab,No,30.61152,30.61152,FULLY REIMBURSABLE,30.61152,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-05-12,,02495732,Vyndaqel,20 mg,Cap,$133.5700,133.57,,20 mg Cap,No,144.2556,144.2556,FULLY REIMBURSABLE,144.2556,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-05-06,,02492504,Dupixent,200 mg /1.14 mL,Inj Sol-1.14 mL Pref Syr (Preservative-Free),$978.7000,978.7,,200 mg /1.14 mL Inj Sol-1.14 mL Pref Syr (Preservative-Free),No,1056.996,1056.996,FULLY REIMBURSABLE,1056.996,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-05-06,,02470365,Dupixent,150 mg / mL,Inj Sol-2 mL Pref Syr (Preservative-Free),$978.7000,978.7,,150 mg / mL Inj Sol-2 mL Pref Syr (Preservative-Free),No,1056.996,1056.996,FULLY REIMBURSABLE,1056.996,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-04-30,,02337819,Extavia,0.3 mg,Pd for Inj - Vial,$104.6920,104.692,,0.3 mg Pd for Inj - Vial,No,113.06736,113.06736,FULLY REIMBURSABLE,113.06736,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-04-30,,02437333,Iclusig,15 mg,Tab,$157.0815,157.0815,,15 mg Tab,No,169.64802,169.64802,FULLY REIMBURSABLE,169.64802,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-04-30,,02437341,Iclusig,45 mg,Tab,$351.0267,351.0267,,45 mg Tab,No,379.108836,379.108836,FULLY REIMBURSABLE,379.108836,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-04-30,,02434407,Imbruvica,140 mg,Cap,$99.8350,99.835,,140 mg Cap,No,107.8218,107.8218,FULLY REIMBURSABLE,107.8218,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-04-30,,02459132,Movapo,10 mg / mL,Inj Sol-Pref Pen 3 mL Pk,$45.5400/Pref Pen,45.54,Pref Pen,10 mg / mL Inj Sol-Pref Pen 3 mL Pk,Yes,49.1832,49.1832,FULLY REIMBURSABLE,49.1832,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-04-30,,02466236,Rydapt,25 mg,Cap,$172.6250,172.625,,25 mg Cap,No,186.435,186.435,FULLY REIMBURSABLE,186.435,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-04-30,,02326442,Tykerb,250 mg,Tab,$24.7910,24.791,,250 mg Tab,No,26.77428,26.77428,FULLY REIMBURSABLE,26.77428,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-04-30,,02286386,Tysabri,300 mg /15 mL,Inj Sol-15 mL Vial Pk,"$3,596.1729",3596.1729,,300 mg /15 mL Inj Sol-15 mL Vial Pk,Yes,3883.866732,3883.866732,FULLY REIMBURSABLE,3883.866732,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-04-30,,02260565,Xolair,150 mg,Inj Pd-6 mL Vial Pk,$652.9800/Vial,652.98,Vial,150 mg Inj Pd-6 mL Vial Pk,Yes,705.2184,705.2184,FULLY REIMBURSABLE,705.2184,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-04-30,,02436779,Zykadia,150 mg,Cap,$53.3880,53.388,,150 mg Cap,No,57.65904,57.65904,FULLY REIMBURSABLE,57.65904,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-04-22,,02436523,Ferriprox,100 mg / mL,Oral Solution,$3.3495/ mL,3.3495,mL,100 mg / mL Oral Solution,No,3.61746,3.61746,FULLY REIMBURSABLE,3.61746,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-04-20,,02415690,Opsumit,10 mg,Tab,$132.0550,132.055,,10 mg Tab,No,142.6194,142.6194,FULLY REIMBURSABLE,142.6194,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-04-08,,02469596,Kanuma,2 mg / mL,Inj Sol-10 mL Vial Pk (Preservative-Free),$8546.0000,8546.0,,2 mg / mL Inj Sol-10 mL Vial Pk (Preservative-Free),Yes,9229.68,9229.68,FULLY REIMBURSABLE,9229.68,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-04-08,,02489252,Onpattro,2 mg / mL,Inj Sol (Preservative-Free),$2100.4813/ mL,2100.4813,mL,2 mg / mL Inj Sol (Preservative-Free),No,2268.519804,2268.519804,FULLY REIMBURSABLE,2268.519804,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-03-25,,02472104,Lonsurf,15 mg & 6.14 mg,Tab,$76.2500,76.25,,15 mg & 6.14 mg Tab,No,82.35,82.35,FULLY REIMBURSABLE,82.35,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-03-25,,02472112,Lonsurf,20 mg & 8.19 mg,Tab,$78.5385,78.5385,,20 mg & 8.19 mg Tab,No,84.82158,84.82158,FULLY REIMBURSABLE,84.82158,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-03-03,,02484137,Verkazia,0.1% w/v,Top Oph Emuls-0.3 mL Pk,$3.6667/single-dose container,3.6667,single-dose container,0.1% w/v Top Oph Emuls-0.3 mL Pk,Yes,3.960036,3.960036,FULLY REIMBURSABLE,3.960036,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-02-26,,02465493,Cubicin RF,500 mg /Vial,Pd for Inj Sol-Vial Pk,$161.0000/Vial,161.0,Vial,500 mg /Vial Pd for Inj Sol-Vial Pk,Yes,173.88,173.88,FULLY REIMBURSABLE,173.88,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-02-02,,02480948,Takhzyro,300 mg /2 mL,Inj Sol-Vial (Preservative-Free),$68.4600/ mg,68.46,mg,300 mg /2 mL Inj Sol-Vial (Preservative-Free),No,73.9368,73.9368,FULLY REIMBURSABLE,73.9368,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2021-01-29,,02481383,Tegsedi,284 mg /1.5 mL,Inj Sol-1.5 mL Pref Syr,"$8,043.4874",8043.4874,,284 mg /1.5 mL Inj Sol-1.5 mL Pref Syr,No,8686.966392,8686.966392,FULLY REIMBURSABLE,8686.966392,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2020-04-28,,02470179,Mavenclad,10 mg,Tab,$3212.0000,3212.0,,10 mg Tab,No,3468.96,3468.96,FULLY REIMBURSABLE,3468.96,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2020-03-31,,02292165,Duodopa,20 mg / mL & 5 mg / mL,Intestinal Gel (100 mL Cassette),$169.8100,169.81,,20 mg / mL & 5 mg / mL Intestinal Gel (100 mL Cassette),No,183.3948,183.3948,FULLY REIMBURSABLE,183.3948,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2020-03-04,,02483971,Cresemba,100 mg,Cap,$78.8300,78.83,,100 mg Cap,No,85.1364,85.1364,FULLY REIMBURSABLE,85.1364,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2020-03-04,,02483998,Cresemba,200 mg /Vial,Pd for Sol-Vial Pk (Preservative-Free),$400.0000/Vial,400.0,Vial,200 mg /Vial Pd for Sol-Vial Pk (Preservative-Free),Yes,432.0,432.0,FULLY REIMBURSABLE,432.0,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2020-02-26,,02471574,Velphoro,500 mg,Chew Tab,$4.2036,4.2036,,500 mg Chew Tab,No,4.539888,4.539888,FULLY REIMBURSABLE,4.539888,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2020-01-22,,02469375,Prevymis,240 mg,Tab,$238.7160,238.716,,240 mg Tab,No,257.81328,257.81328,FULLY REIMBURSABLE,257.81328,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2020-01-22,,02469367,Prevymis,20 mg / mL,Inj Sol-240 mL Vial Pk,$238.7160,238.716,,20 mg / mL Inj Sol-240 mL Vial Pk,Yes,257.81328,257.81328,FULLY REIMBURSABLE,257.81328,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2020-01-22,,02469383,Prevymis,480 mg,Tab,$238.7160,238.716,,480 mg Tab,No,257.81328,257.81328,FULLY REIMBURSABLE,257.81328,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2020-01-22,,02469405,Prevymis,20 mg / mL,Inj Sol-480 mL Vial Pk,$469.0910,469.091,,20 mg / mL Inj Sol-480 mL Vial Pk,Yes,506.61828,506.61828,FULLY REIMBURSABLE,506.61828,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2019-11-11,,02484013,Brineura,30 mg / mL,Inj Sol-5 mL Vial Pk,$100.6667/ mg,100.6667,mg,30 mg / mL Inj Sol-5 mL Vial Pk,Yes,108.720036,108.720036,FULLY REIMBURSABLE,108.720036,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2019-09-12,,02467224,Ocrevus,30 mg / mL,Inj Sol-10 mL Vial Pk (Preservative Free),$8150.0000/Vial,8150.0,Vial,30 mg / mL Inj Sol-10 mL Vial Pk (Preservative Free),Yes,8802.0,8802.0,FULLY REIMBURSABLE,8802.0,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2019-06-28,,02443066,Ofev,100 mg,Cap,$28.4168,28.4168,,100 mg Cap,No,30.690144,30.690144,FULLY REIMBURSABLE,30.690144,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2019-06-28,,02443074,Ofev,150 mg,Cap,$56.8336,56.8336,,150 mg Cap,No,61.380288,61.380288,FULLY REIMBURSABLE,61.380288,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2019-05-13,,02468042,Galafold,123 mg,Cap,$1700.0000,1700.0,,123 mg Cap,No,1836.0,1836.0,FULLY REIMBURSABLE,1836.0,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2019-05-13,,02427184,Vimizim,5 mg /5 mL,Inj Sol-5 mL Vial Pk (Preservative Free),$1091.0900/Vial,1091.09,Vial,5 mg /5 mL Inj Sol-5 mL Vial Pk (Preservative Free),Yes,1178.3772,1178.3772,FULLY REIMBURSABLE,1178.3772,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2019-04-30,,02247725,Fuzeon,108 mg /Vial,Inj-3 mL Vial Pk,$42.3230,42.323,,108 mg /Vial Inj-3 mL Vial Pk,Yes,45.70884,45.70884,FULLY REIMBURSABLE,45.70884,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2019-04-30,,02388006,Jakavi,5 mg,Tab,$86.6275,86.6275,,5 mg Tab,No,93.5577,93.5577,FULLY REIMBURSABLE,93.5577,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2019-04-30,,2241927,Rituxan,10 mg / mL,Inj-10 mL Vial Pk,$482.3050/Vial,482.305,Vial,10 mg / mL Inj-10 mL Vial Pk,Yes,520.8894,520.8894,FULLY REIMBURSABLE,520.8894,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2019-04-30,,09857407,Rituxan,10 mg / mL,Inj-50 mL Vial Pk,$2411.5400/Vial,2411.54,Vial,10 mg / mL Inj-50 mL Vial Pk,Yes,2604.4632,2604.4632,FULLY REIMBURSABLE,2604.4632,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2019-04-10,,02418320,Lemtrada,12 mg /1.2 mL,Inj Sol-12 mg /1.2 mL Vial,$1085.9258/ mg,1085.9258,mg,12 mg /1.2 mL Inj Sol-12 mg /1.2 mL Vial,No,1172.799864,1172.799864,FULLY REIMBURSABLE,1172.799864,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2019-02-04,,02442302,Quinsair,100 mg / mL,Inh Sol-2.4 mL Amp (Preservative Free),$64.4887/amp,64.4887,amp,100 mg / mL Inh Sol-2.4 mL Amp (Preservative Free),No,69.647796,69.647796,FULLY REIMBURSABLE,69.647796,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2018-11-20,,02465663,Spinraza,2.4 mg / mL,Inj Sol-5 mL Vial Pk,$9833.3333/ mg,9833.3333,mg,2.4 mg / mL Inj Sol-5 mL Vial Pk,Yes,10619.999964,10619.999964,FULLY REIMBURSABLE,10619.999964,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2018-10-29,,02457857,Hemangiol,3.75 mg / mL,Oral Sol,$2.2808,2.2808,,3.75 mg / mL Oral Sol,No,2.463264,2.463264,FULLY REIMBURSABLE,2.463264,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2018-09-13,,02378582,Caprelsa,100 mg,Tab,$99.1573,99.1573,,100 mg Tab,No,107.089884,107.089884,FULLY REIMBURSABLE,107.089884,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2018-09-13,,02378590,Caprelsa,300 mg,Tab,$198.3150,198.315,,300 mg Tab,No,214.1802,214.1802,FULLY REIMBURSABLE,214.1802,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2018-06-29,,02329840,Cayston,75 mg /vial,Pd Inh Sol- Vial Pk,$42.3989,42.3989,,75 mg /vial Pd Inh Sol- Vial Pk,Yes,45.790812,45.790812,FULLY REIMBURSABLE,45.790812,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2018-06-06,,02444615,Strensiq,18 mg /0.45 mL,Single Use Vial,$1358.6400,1358.64,,18 mg /0.45 mL Single Use Vial,No,1467.3312,1467.3312,FULLY REIMBURSABLE,1467.3312,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2018-06-06,,02444623,Strensiq,28 mg /0.7 mL,Single Use Vial,$2113.4400,2113.44,,28 mg /0.7 mL Single Use Vial,No,2282.5152,2282.5152,FULLY REIMBURSABLE,2282.5152,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2018-06-06,,02444631,Strensiq,40 mg /1 mL,Single Use Vial,$3019.2000,3019.2,,40 mg /1 mL Single Use Vial,No,3260.736,3260.736,FULLY REIMBURSABLE,3260.736,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2018-06-06,,02444658,Strensiq,80 mg /0.8 mL,Single Use Vial,$6038.4000,6038.4,,80 mg /0.8 mL Single Use Vial,No,6521.472,6521.472,FULLY REIMBURSABLE,6521.472,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2018-04-19,,02460351,Ilaris,150 mg / mL,Inj Sol-Vial Pk,$106.6667 per mg,106.6667,,150 mg / mL Inj Sol-Vial Pk,Yes,115.200036,115.200036,FULLY REIMBURSABLE,115.200036,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2018-04-19,,02282097,Orencia,250 mg /Vial,Inj Pd-Vial Pk,$500.3411,500.3411,,250 mg /Vial Inj Pd-Vial Pk,Yes,540.368388,540.368388,FULLY REIMBURSABLE,540.368388,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2018-04-19,,02402475,Orencia (Preservative Free),125 mg / mL,Inj Sol-Pref Syr-1 mL Pk,$373.7881,373.7881,,125 mg / mL Inj Sol-Pref Syr-1 mL Pk,Yes,403.691148,403.691148,FULLY REIMBURSABLE,403.691148,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2018-04-09,,02453304,Ravicti,1.1 g / mL,Oral Liquid,$48.0000,48.0,,1.1 g / mL Oral Liquid,No,51.84,51.84,FULLY REIMBURSABLE,51.84,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2017-03-28,,02386666,Seacalphyx,250 mg / mL,Inj Sol,$2.7500/ mL,2.75,mL,250 mg / mL Inj Sol,No,2.97,2.97,FULLY REIMBURSABLE,2.97,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2016-10-19,,02438798,Zydelig,100 mg,Tab,$85.3500,85.35,,100 mg Tab,No,92.178,92.178,FULLY REIMBURSABLE,92.178,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2016-10-19,,02438801,Zydelig,150 mg,Tab,$85.3500,85.35,,150 mg Tab,No,92.178,92.178,FULLY REIMBURSABLE,92.178,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2016-09-16,,02413175,Simponi,100 mg /1.0 mL,Pre-Filled Syringe,$1555.1700,1555.17,,100 mg /1.0 mL Pre-Filled Syringe,No,1679.5836,1679.5836,FULLY REIMBURSABLE,1679.5836,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2016-09-16,,02413183,Simponi,100 mg /1.0 mL,Auto-Injector,$1555.1700,1555.17,,100 mg /1.0 mL Auto-Injector,No,1679.5836,1679.5836,FULLY REIMBURSABLE,1679.5836,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2016-04-29,,02407329,Xtandi,40 mg,Cap,$29.1954,29.1954,,40 mg Cap,No,31.531032,31.531032,FULLY REIMBURSABLE,31.531032,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2016-01-28,,02387174,Dificid,200 mg,Tab,$94.60,94.6,,200 mg Tab,No,102.168,102.168,FULLY REIMBURSABLE,102.168,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2016-01-28,,02324784,Simponi,50 mg /0.5 mL,Auto-Injector,"$1,555.17",1555.17,,50 mg /0.5 mL Auto-Injector,No,1679.5836,1679.5836,FULLY REIMBURSABLE,1679.5836,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2016-01-28,,02324776,Simponi,50 mg /0.5 mL,Pre-Filled Syringe,"$1,555.17",1555.17,,50 mg /0.5 mL Pre-Filled Syringe,No,1679.5836,1679.5836,FULLY REIMBURSABLE,1679.5836,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2015-07-10,,02334852,Norditropin Nordiflex,5 mg /1.5 mg,Inj Sol-Pref Pen,$194.7000,194.7,,5 mg /1.5 mg Inj Sol-Pref Pen,No,210.276,210.276,FULLY REIMBURSABLE,210.276,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2015-07-10,,02334860,Norditropin Nordiflex,10 mg /1.5 mg,Inj Sol-Pref Pen,$389.4000,389.4,,10 mg /1.5 mg Inj Sol-Pref Pen,No,420.552,420.552,FULLY REIMBURSABLE,420.552,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2015-07-10,,02334879,Norditropin Nordiflex,15 mg /1.5 mg,Inj Sol-Pref Pen,$584.1000,584.1,,15 mg /1.5 mg Inj Sol-Pref Pen,No,630.828,630.828,FULLY REIMBURSABLE,630.828,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2015-02-26,,02403390,Stivarga,40 mg,Tab,$72.6200,72.62,,40 mg Tab,No,78.4296,78.4296,FULLY REIMBURSABLE,78.4296,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2014-06-20,,02397412,Kalydeco,150 mg,Tab,$420.0000,420.0,,150 mg Tab,No,453.6,453.6,FULLY REIMBURSABLE,453.6,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2014-04-16,,02371553,Incivek,375 mg,Tab,$69.3810,69.381,,375 mg Tab,No,74.93148,74.93148,FULLY REIMBURSABLE,74.93148,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2014-01-30,,02244016,Remicade,100 mg /10 mL,Injection,$987.5600,987.56,,100 mg /10 mL Injection,No,1066.5648,1066.5648,FULLY REIMBURSABLE,1066.5648,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2014-01-30,,02284227,Nexavar,200 mg,Tab,$46.4689,46.4689,,200 mg Tab,No,50.186412,50.186412,FULLY REIMBURSABLE,50.186412,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2013-02-20,,02350580,Kuvan,100 mg,Tab,$33.0000,33.0,,100 mg Tab,No,35.64,35.64,FULLY REIMBURSABLE,35.64,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2012-09-13,,02355191,Thalomid,50 mg,Cap,$29.4690,29.469,,50 mg Cap,No,31.82652,31.82652,FULLY REIMBURSABLE,31.82652,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2012-09-13,,02355205,Thalomid,100 mg,Cap,$58.9380,58.938,,100 mg Cap,No,63.65304,63.65304,FULLY REIMBURSABLE,63.65304,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2012-09-13,,02355221,Thalomid,200 mg,Cap,$117.8800,117.88,,200 mg Cap,No,127.3104,127.3104,FULLY REIMBURSABLE,127.3104,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2012-08-27,,02325063,Omnitrope,5 mg /1.5 mL,Inj-5 mg Pen Cart Pk,$155.8000,155.8,,5 mg /1.5 mL Inj-5 mg Pen Cart Pk,Yes,168.264,168.264,FULLY REIMBURSABLE,168.264,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2012-08-27,,02325071,Omnitrope,10 mg /1.5 mL,Inj-10 mg Pen Cart Pk,$311.6000,311.6,,10 mg /1.5 mL Inj-10 mg Pen Cart Pk,Yes,336.528,336.528,FULLY REIMBURSABLE,336.528,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2012-03-19,,02344939,Ilaris,150 mg,Powder for solution for sc injection (vial),$106.6667/ mg,106.6667,mg,150 mg Powder for solution for sc injection (vial),No,115.200036,115.200036,FULLY REIMBURSABLE,115.200036,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2011-10-27,,02357119,Vpriv ®,400 U,Vial,$1955.0000,1955.0,,400 U Vial,No,2111.4,2111.4,FULLY REIMBURSABLE,2111.4,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2009-10-08,,02169649,Betaseron,Inj Pref Syr — 0.3 mg,Injection,$110.0000,110.0,,Inj Pref Syr — 0.3 mg Injection,No,118.8,118.8,FULLY REIMBURSABLE,118.8,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2009-06-11,,02284863,Myozyme,50 mg /vial,Lyophylized Powder,$840.3100,840.31,,50 mg /vial Lyophylized Powder,No,907.5348,907.5348,FULLY REIMBURSABLE,907.5348,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
2009-05-27,,02296314,Elaprase,2 mg / mL,3 mL Vial,"$3,800.00",3800.0,,2 mg / mL 3 mL Vial,No,4104.0,4104.0,FULLY REIMBURSABLE,4104.0,,"DRUGS FUNDED BY EAP. THERE EXISTS AN ADDITIONAL COPAYMENT BASED ON PATIENT'S AGE/INCOME ($6.11/PRESCRIPTION FOR 65 YEARS & OLD, INCOME ABOVE $19,300; $2/PRESCRIPTION FOR 65 YEARS OLD, INCOME BELOW $19,300 & FOR POPULATION UNDER TRILLIUM DRUG PROGRAM)",0.0
